Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MDGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDGLMadrigal Pharmaceuticals$301.66-2.0%$329.57$189.00▼$377.46$6.80B-0.69392,791 shs238,598 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDGLMadrigal Pharmaceuticals-1.99%-1.85%-10.89%+2.73%+32.11%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMDGLMadrigal Pharmaceuticals4.4537 of 5 stars3.42.00.04.64.14.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMDGLMadrigal Pharmaceuticals 2.80Moderate Buy$378.4425.45% UpsideCurrent Analyst Ratings BreakdownLatest MDGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/27/2025MDGLMadrigal PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy$236.00 ➝ $422.002/27/2025MDGLMadrigal PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$378.00 ➝ $469.002/27/2025MDGLMadrigal PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$400.00 ➝ $405.00(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMDGLMadrigal Pharmaceuticals$180.13M36.98N/AN/A$20.53 per share14.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMDGLMadrigal Pharmaceuticals-$373.63M-$22.11N/AN/AN/AN/A-71.78%-53.25%5/6/2025 (Estimated)Latest MDGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025MDGLMadrigal Pharmaceuticals-$3.66N/AN/AN/A$112.79 millionN/A2/26/2025Q4 2024MDGLMadrigal Pharmaceuticals-$4.32-$2.71+$1.61-$2.71$97.81 million$103.32 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMDGLMadrigal Pharmaceuticals0.155.985.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMDGLMadrigal Pharmaceuticals98.50%Insider OwnershipCompanyInsider OwnershipMDGLMadrigal Pharmaceuticals22.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMDGLMadrigal Pharmaceuticals9022.08 million16.84 millionOptionableMDGL HeadlinesRecent News About These CompaniesMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Rating of "Moderate Buy" by BrokeragesApril 18 at 2:07 AM | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is Affinity Asset Advisors LLC's 7th Largest PositionApril 17 at 7:52 AM | marketbeat.comRossby Financial LCC Acquires Shares of 1,048 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)April 17 at 6:25 AM | marketbeat.comReviewing Pliant Therapeutics (NASDAQ:PLRX) and Madrigal Pharmaceuticals (NASDAQ:MDGL)April 17 at 2:02 AM | americanbankingnews.comMadrigal announces Taub to become Senior Scientific, Medical AdvisorApril 16 at 2:27 PM | markets.businessinsider.comMadrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D.April 16 at 7:00 AM | globenewswire.comUniversity of Wisconsin Foundation Reduces Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)April 15 at 8:18 AM | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Acquired by Franklin Resources Inc.April 15 at 3:39 AM | marketbeat.comWellington Management Group LLP Has $2.52 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)April 15 at 3:39 AM | marketbeat.com2,259 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Bought by F M Investments LLCApril 14, 2025 | marketbeat.comFmr LLC Raises Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)April 14, 2025 | marketbeat.comRenaissance Technologies LLC Grows Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)April 13, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Alliancebernstein L.P.April 12, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stock Holdings Raised by Geode Capital Management LLCApril 11, 2025 | marketbeat.comCapula Management Ltd Buys Shares of 1,148 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)April 10, 2025 | marketbeat.comCalifornia Public Employees Retirement System Sells 985 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)April 9, 2025 | marketbeat.com3,624 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Bought by Landscape Capital Management L.L.C.April 8, 2025 | marketbeat.comPrudential Financial Inc. Acquires 2,282 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)April 8, 2025 | marketbeat.comCIBC Private Wealth Group LLC Decreases Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)April 7, 2025 | marketbeat.comSchroder Investment Management Group Trims Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)April 7, 2025 | marketbeat.comNorges Bank Takes $35.51 Million Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)April 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDGL Company DescriptionsMadrigal Pharmaceuticals NASDAQ:MDGL$301.66 -6.12 (-1.99%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$301.47 -0.19 (-0.06%) As of 04/17/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk Tariff-Resistant Abbott Laboratories on Track for New Highs Goldman Sachs Just Revealed What’s Next for Markets United Airlines Is in Reversal—If the Economy Doesn’t Stall Buy the Boeing Dip Even on Tariff and Bans? Spotify Stock Climbs as Its Growth Strategy Diversifies Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
